Syndax and Merck explore entinostat/Keytruda combination
Syndax Pharmaceuticals Inc. and Merck & Co. Inc. will conduct a Phase Ib/II trial to study the combination of Syndax’s HDAC inhibitor entinostat with Merck’s Keytruda (pembrolizumab) for advanced non-small cell lung cancer (NSCLC) or melanoma.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.